검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Gemcitabine and nab-paclitaxel (Gemcitabine and nab-paclitaxel) Orion Corporation, Orion Pharma·Anal Cancer Metastatic ORR 80% |
|---|---|
Overview Program | Gemcitabine and nab-paclitaxel |
Overview Company | Orion Corporation, Orion Pharma |
Overview Modality | ANTIBODY |
Overview Target | Anal Cancer Metastatic |
Overview Indication | Mesothelioma; Pancreatic Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | of ProAgio, which includes reducing hypoxia and modulating TME |
MoA Biomarker | Biomarker Monitoring |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer.. Pancreas cancer (PCa) is one of the mortal cancer types with ranking as fourth leading cancer death in both sexes together. FOLFIRINOX (FFX) and Gemcitabine plus nab-paclitaxel (GNP) are approved as first-line metastatic treatment in PCa. The aim of this study was to compare the clini… |
Clinical Primary efficacy | ORR 80% |
Clinical ORR | 80.0% |
Clinical PFS | 10 |
Clinical OS | 33.6 |
Clinical Result source | ClinicalTrials.gov NCT02759588 |
Clinical Data Tier / Score | A · 69 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Gemcitabine and nab-paclitaxel (Gemcitabine and nab-paclitaxel) Orion Corporation, Orion Pharma·Anal Cancer Metastatic ORR 80% |
|---|---|
Overview Program | Gemcitabine and nab-paclitaxel |
Overview Company | Orion Corporation, Orion Pharma |
Overview Modality | ANTIBODY |
Overview Target | Anal Cancer Metastatic |
Overview Indication | Mesothelioma; Pancreatic Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | of ProAgio, which includes reducing hypoxia and modulating TME |
MoA Biomarker | Biomarker Monitoring |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer.. Pancreas cancer (PCa) is one of the mortal cancer types with ranking as fourth leading cancer death in both sexes together. FOLFIRINOX (FFX) and Gemcitabine plus nab-paclitaxel (GNP) are approved as first-line metastatic treatment in PCa. The aim of this study was to compare the clini… |
Clinical Primary efficacy | ORR 80% |
Clinical ORR | 80.0% |
Clinical PFS | 10 |
Clinical OS | 33.6 |
Clinical Result source | ClinicalTrials.gov NCT02759588 |
Clinical Data Tier / Score | A · 69 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교